Shares of Replimune (REPL) surged today after the company announced their presentation 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting. The stock finished strong on Wednesday.
The biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, announced that data with the Company’s lead product candidate, RP1, along with initial single agent safety and efficacy data with RP2 in advanced solid tumors, will be presented at the Society for Immunotherapy of Cancer (SITC) annual meeting being held virtually from November 9-14, 2020.
The abstracts for these presentations appeared briefly and in error on the SITC website this morning, prior to their intended release on November 9th 2020.
Should you invest in Replimune (REPL)?
Shares of Replimune (REPL) appear to be a very good investment option, the Money Midnight Indicator is expecting its price to increase considerably in the next of years. The majority of the metrics point to this investment being highly attractive.
